Keith Dionne, Ph.D. Appointed CEO of Luxa Biotechnology

Fort Lee, NJ, October 1, 2024 (Business Wire) -- Dr. Keith Dionne has been appointed as the CEO of Luxa Biotechnology, where he will lead the development of a novel RPESC therapy for dry AMD. With 30 years of experience in biotechnology and cell therapy, Dr. Dionne is well-equipped to drive the company's mission forward. His previous leadership roles and extensive expertise in guiding early-stage biotech firms to success position him as the ideal leader for Luxa's vision.

Read full article here.